Gynecologic, Ovarian, and Cervical Cancer

GYNECOLOGIC CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Multitumor “Exceptional Responder” Program in Australia Seeks to Gain Clinical Context

The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response.
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer

In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
Dual-Targeted CAR-T Therapies in Solid Tumors: Q&A With Dr Wayne Marasco

Dr Marasco explains that CAR-T therapies are really “cellular therapies that work by way of gene manipulation,” and describes a method through which he hopes CAR-T can produce durable, long-term treatments for solid tumors.
Research Shows How Talc Powder May Change Ovarian Cancer Cells

Prospective studies on talc and cancer are necessary to fully form our collective understanding of talc’s risks.
Boost in Frontline Bevacizumab Use in Ovarian Cancer Linked to Guidelines Inclusion

Addition of bevacizumab to NCCN guidelines as a frontline therapy in ovarian cancer spurred more utilization of the drug than did fresh findings from clinical trials.

GYNECOLOGIC CANCER NEWS

A patient undergoes cancer-related surgery.

Secondary Surgical Cytoreduction Not Superior in Ovarian Cancer

November 15, 2019

Cancer Screening Rates Lower Among Women With Diabetes

October 30, 2019

The decade-long paradigm shift in decoding ovarian cancer is only now beginning to make its way from

Addition of Bevacizumab to Anti–PD-1 Therapy Improved Response Rate in Recurrent Ovarian Cancer

October 24, 2019

Treatment advances over recent years render much of the previously used evidence outdated.

Maintenance Olaparib Found to Provide a PFS Benefit in Advanced Ovarian Cancer

October 4, 2019

Female reproductive system

Oophorectomy More Effective Than Ultrasound Screening in Preventing BRCA1-Related Ovarian Cancer

September 26, 2019

Next post in Gynecologic Cancer

In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.

Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer